Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Mar 21, 2024 6:17pm
239 Views
Post# 35945987

RE:(News Release)

RE:(News Release)Let me help Duster ...
1.  I highly doubt that anyone is trying to control this stock price ... don't think anyone ever tried to do that.  Would love to meet them.
2.  No information - true.
3.  The insider buying was timed quickly ... so likely as a message to investors.  They never buy in reoccurring events and it would be surprising to see it again this month.
4.  Good news - that's what the poster is all about.
5.  Uncertainty - sure !  If you don't have think skin by now, you won't have it.
6.  No need to touch it with any kind of pole - here's how investors are touching it and it isn't new ... they usually drive it up as they pick away and at some price, someone else offloads at market - making an exit for the doors, hitting new lows.  Drive it up for a bit and then someone offloads as they head for the doors.  Same old - same old.

Do you think you will ever again use that pole of yours to make a purchase ?      

: )
<< Previous
Bullboard Posts
Next >>